Clinical trials: Kerato Conjunctivitis Sicca
Dry Eye Syndrome
Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye
The purpose of this study is to compare the safety and efficacy of RX-10045 to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT00799552
- Testing
- RX-10045
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Resolvyx Pharmaceuticals, Inc
Dry Eye Disease
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
The purpose of this study is to evaluate the percentage of ocular adverse events reported in subjects with dry eye disease (DED) between the intervention arm (0.003% AR-15512) and control arm (REFRESH® Classic).
- Trial name
- NCT06660290
- Testing
- 0.003% AR-15512 ophthalmic solution, Artificial tears
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Dry Eye Syndromes, Dry Eye Disease
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
- Conditions
- Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05848128
- Testing
- 5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution
- Where
- 29 sites in United States
- Volunteers
- 642 people
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
- Trial name
- NCT02526290
- Testing
- Intranasal Lacrimal Neurostimulator (Oculeve)
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Oculeve, Inc.
Keratoconjunctivitis Sicca
Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye
Comparative efficacy trial of INS365 Ophthalmic Solution and placebo in patients with dry eye.
- Trial name
- NCT00037661
- Testing
- INS365 Ophthalmic Solution
- Volunteers
- 222 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.